The Harvard Skin Disease Research Core Center (HSDRC) grant has funded Core services and Pilot and Feasibility Studies throughout Harvard and its affiliated hospitals for nearly 15 years. Our Center's initiatives have helped build a vibrant community of scientists (Research Base) who have made a major impact on biomedical research relevant to skin. Nearly half of the current Research Base members are new additions. Our Core facilities have provided scientists unfamiliar with skin diseases, or skin as a model of disease, with easy access to highly specialized services and resources. Our P&F Project Program has funded 46 innovative proposals over the past ten years. In aggregate, HSDRC funding has led to hundreds of published papers and has enabled many new extramural grants from the NIH as well as other sources. We estimate that the P&F Program alone has yielded a >20-fold """"""""return on investment"""""""", as judged by subsequent funding that resulted from the P&F studies. In the present proposal, four service Core facilities are proposed. The Cell Culture Core will provide a broad range of services and unique cells/cell lines to the HSDRC community, and will introduce inducible pluripotent stem cell (IPS) approaches. The Morphology and Cell Analysis Core will provide highly specialized and unique general and molecular pathology services. The Transgenic and Mouse Models Core will provide state-of-the-art approaches to the generation of transgenic mice relevant to the study of skin. The Leukocyte Migration Core will provide unique services to study the biology and biophysics of immune and stem cell migration. Four highly innovative P&F studies are proposed, each of which uses services from at least one of the Cores. Finally, two pilot Cores are proposed, which are supported entirely by institutional funds. A Translational Research Resources Core is designed to facilitate skin disease research using clinical materials and on human subjects, and a Chemical Biology Core will use new and high throughput approaches to screen compounds relevant to skin disease. An Administrative Core, bolstered by considerable institutional support, ensures that the Cores and P&F studies are managed successfully with regard to operations, budget, and resources. We are confidant that the HSDRC will continue to make a major impact on skin diseases research.

Public Health Relevance

Our ability to successfully treat patients with skin diseases, including skin cancers, depends on our ability to better understand the physiology of skin, to uncover mechanisms of disease, and to identify potential therapeutic targets. These three goals are the major focus of the Harvard Skin Disease Research Core Center, and are facilitated by its specialized Core services and Pilot Study funding.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
2P30AR042689-16
Application #
7666408
Study Section
Special Emphasis Panel (ZAR1-KM-D (M1))
Program Officer
Cibotti, Ricardo
Project Start
2010-04-14
Project End
2011-10-13
Budget Start
2010-04-14
Budget End
2011-10-13
Support Year
16
Fiscal Year
2010
Total Cost
$668,878
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Tian, Tian; Jin, Michelle Qiushuang; Dubin, Krista et al. (2017) IL-1R Type 1-Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection. J Immunol 198:4341-4351
Pan, Youdong; Tian, Tian; Park, Chang Ook et al. (2017) Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 543:252-256
Volpicelli, Elgida R; Lezcano, Cecilia; Zhan, Qian et al. (2014) The multidrug-resistance transporter ABCB5 is expressed in human placenta. Int J Gynecol Pathol 33:45-51
Guenova, Emmanuella; Watanabe, Rei; Teague, Jessica E et al. (2013) TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19:3755-63
Majewska-Szczepanik, Monika; Paust, Silke; von Andrian, Ulrich H et al. (2013) Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon-?, interferon-? and interleukin-12. Immunology 140:98-110
Zadran, Sohila; McMickle, Robert; Shackelford, David et al. (2013) Monitoring extra-vascular migratory metastasis (EVMM) of migrating cancer cells using an in vitro co-culture system. Protoc exch 2013:
Burkhardt, Ute E; Hainz, Ursula; Stevenson, Kristen et al. (2013) Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 123:3756-65
Dowlatshahi, Mitra; Huang, Victor; Gehad, Ahmed E et al. (2013) Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 133:1879-89
Seneschal, Julien; Clark, Rachael A; Gehad, Ahmed et al. (2012) Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36:873-84
Girouard, Sasha D; Laga, Alvaro C; Mihm, Martin C et al. (2012) SOX2 contributes to melanoma cell invasion. Lab Invest 92:362-70

Showing the most recent 10 out of 113 publications